# US 2023/0272017 A1 · Modified nanopores, compositions comprising the same, and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0272017 A1
- Document ID: US20230272017A1
- Status: Published application
- Kind: A1
- Application number: 18/045,599
- Filed: 2022-10-11
- Published: 2023-08-31
- Earliest claimed: 2017-02-10
- Assignees: Oxford Nanopore Technologies PLC
- Applicants: Oxford Nanopore Technologies PLC
- Inventors: Lakmal Nishantha Jayasinghe; Elizabeth Jayne Wallace; Pratik Raj Singh
- Web page: https://patentgrep.com/patent/US20230272017A1

## CPC

- C07K 14/195: from bacteria
- C12Q 1/6869: Methods for sequencing
- B82Y 30/00: Nanotechnology for materials or surface science, e.g. nanocomposites
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

Provided herein relate to modified or mutant forms of secretin and compositions comprising the same. In particular, the modified or mutant forms of secretin permits efficient capture and/or translocation of an analyte through the modified or mutant secretin nanopores. Methods for using unmodified secretin or the modified or mutant forms of secretin and compositions, for example, for characterizing an analyte, e.g., a target polynucleotide, are also provided.

## Claims

### Claim at position 1

1-71. (canceled)

### Claim 72

A method of detecting the presence or absence of an analyte in a sample and/or characterising an analyte in a sample, the method comprising contacting a secretin nanopore disposed in a membrane with the sample, applying a voltage gradient across the membrane and detecting ionic current flow through the nanopore.

### Claim 73 (depends on 72)

The method of claim 72, wherein the secretin nanopore is a modified secretin nanopore.

### Claim 74 (depends on 73)

The method of claim 73, wherein the modified secretin nanopore comprises a lumenal surface defining a lumen that extends through the membrane between a cis-opening and a trans-opening, wherein the lumenal surface comprises one or more amino acid modifications relative to a wild-type secretin nanopore.

### Claim 75 (depends on 74)

The method of claim 74, wherein the one or more amino acid modifications comprise a charge-altering modification.

### Claim 76 (depends on 75)

The method of claim 75, wherein the charge-altering modification is a substitution of a negatively-charged amino acid with a positively-charged amino acid.

### Claim 77 (depends on 74)

The method of claim 74, wherein the one or more amino acid modifications comprise a substitution of a neutral amino acid with a hydrophobic amino acid.

### Claim 78 (depends on 74)

The method of claim 74, wherein the cis-opening has a diameter in a range of 60 Å to 120 Å.

### Claim 79 (depends on 74)

The method of claim 74, wherein the trans-opening has a diameter in a range of 40 Å to 100 Å.

### Claim 80 (depends on 74)

The method of claim 74, wherein the secretin nanopore comprises a constriction having a diameter of about 7.5 Å to 25 Å.

### Claim 81 (depends on 74)

The method of claim 74, wherein the secretin is of a type II, type III, or type IV secretion system.

### Claim 82 (depends on 74)

The method of claim 74, wherein the secretin is GspD, YscC, InvG, or PilQ.

### Claim 83 (depends on 74)

The method of claim 74, wherein the modified secretin nanopore comprises a subunit polypeptide having an amino acid sequence that is at least 95% identical to the amino acid sequence as set forth in SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 1 or SEQ ID NO: 2.

### Claim 85 (depends on 74)

The method of claim 74, wherein the secretin is GspD and the GspD does not comprise a cap gate.

### Claim 86 (depends on 74)

The method of claim 74, wherein the secretin is GspD and comprises a central gate that has been modified to replace an amino acid with an amino acid having a smaller side group and/or to replace a negatively charged amino acid with a neutral or positively charged amino acid.

### Claim 87 (depends on 74)

The method of claim 74, wherein the secretin is GspD and the modified secretin nanopore comprises a subunit polypeptide having an amino acid sequence that is at least 95% identical to an amino acid sequence as set forth in SEQ ID NO: 36, wherein: (i) one or more of the amino acids from D55 or T56 to T77 are deleted or substituted, one or more of K60, D64, R71 and E73 is substituted with an uncharged amino acid and/or one or more of D55, T56, T77 and K78 is substituted with P; and/or (ii) F156 is substituted with a smaller amino acid, N151 and/or N152 is/are substituted with a smaller amino acid, D153 is substituted with an uncharged amino acid, G137 and G165 are each independently unmodified or substituted with A or V.

### Claim 88 (depends on 87)

The method of claim 87, wherein Y63 to R71 are deleted and/or substituted with GSG or SGS, F156 is substituted with A, D153 is substituted with S, and/or N151 and N152 are each independently substituted with G or S.

### Claim 95 (depends on 74)

The method of claim 74, wherein the secretin is InvG and the modified secretin nanopore comprises a subunit polypeptide having an amino acid sequence that is at least 95% identical to the amino acid sequence as set forth in SEQ ID NO: 1, wherein the lumenal surface further defines a constriction within the lumen, the constriction having one or more amino acid modifications at amino acids D28, E225, R226, and/or E231 of SEQ ID NO: 1.

### Claim 96 (depends on 95)

The method of claim 95, wherein the one or more amino acid modifications of the constriction comprise one or more of the following:
i. D28N/Q/T/S/G/R/K;
ii. E225N/Q/T/A/S/G/P/H/F/Y/R/K;
iii. R226N/Q/T/A/S/G/P/H/F/Y/K/V;
iv. Deletion of E225;
v. Deletion of R226; and
vi. E231N/Q/T/A/S/G/P/H/R/K.

### Claim 97 (depends on 74)

The method of claim 74, wherein the secretin is InvG and the modified secretin nanopore comprises a subunit polypeptide having an amino acid sequence that is at least 95% identical to the amino acid sequence as set forth in SEQ ID NO: 1, wherein the lumenal surface comprises a capture portion having one or more amino acid modifications at amino acids E41, Q45 or E114.

### Claim 98 (depends on 97)

The method of claim 97, wherein the capture portion comprises one or more of the following amino acid modifications:
i. Q45R/K;
ii. E41N/Q/T/S/G/R/K; and
iii. E114N/Q/T/S/G/R/K.
